Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 209176
Company: MITSUBISHI TANABE
Company: MITSUBISHI TANABE
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
RADICAVA | EDARAVONE | 30MG/100ML (0.3MG/ML) | SOLUTION;INTRAVENOUS | Prescription | AP | Yes | Yes |
RADICAVA | EDARAVONE | 60MG/100ML (0.6MG/ML) | SOLUTION;INTRAVENOUS | Prescription | AP | Yes | Yes |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
05/05/2017 | ORIG-1 | Approval | Type 1 - New Molecular Entity | STANDARD; Orphan |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209176lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/209176Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000TOC.cfm |
Supplements
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
---|---|---|---|---|---|
11/18/2022 | SUPPL-12 | Labeling-Package Insert, Labeling-Patient Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209176s012lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/209176Orig1s012ltr.pdf | |
03/15/2021 | SUPPL-10 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209176s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/209176Orig1s010ltr.pdf | |
11/01/2019 | SUPPL-9 | Labeling-Patient Package Insert, Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209176s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/209176Orig1s009ltr.pdf | |
11/15/2018 | SUPPL-7 | Manufacturing (CMC)-Formulation |
Label (PDF)
Letter (PDF) Review (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209176Orig1s007lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/209176Orig1s007ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209176Orig1s007.pdf | |
08/17/2018 | SUPPL-5 | Labeling-Container/Carton Labels |
Label is not available on this site. |
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
---|---|---|---|---|---|
11/18/2022 | SUPPL-12 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209176s012lbl.pdf | |
11/18/2022 | SUPPL-12 | Labeling-Patient Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209176s012lbl.pdf | |
03/15/2021 | SUPPL-10 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209176s010lbl.pdf | |
11/01/2019 | SUPPL-9 | Labeling-Patient Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209176s009lbl.pdf | |
11/01/2019 | SUPPL-9 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209176s009lbl.pdf | |
11/15/2018 | SUPPL-7 | Manufacturing (CMC)-Formulation | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209176Orig1s007lbl.pdf | |
05/05/2017 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209176lbl.pdf |
RADICAVA
SOLUTION;INTRAVENOUS; 30MG/100ML (0.3MG/ML)
TE Code = AP
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | TE Code | Application No. | Company |
---|---|---|---|---|---|---|---|---|
EDARAVONE | EDARAVONE | 30MG/100ML (0.3MG/ML) | SOLUTION;INTRAVENOUS | Prescription | No | AP | 216199 | GLAND PHARMA LTD |
EDARAVONE | EDARAVONE | 30MG/100ML (0.3MG/ML) | SOLUTION;INTRAVENOUS | Prescription | No | AP | 215508 | HIKMA |
EDARAVONE | EDARAVONE | 30MG/100ML (0.3MG/ML) | SOLUTION;INTRAVENOUS | Prescription | No | AP | 218354 | LONG GROVE PHARMS |
RADICAVA | EDARAVONE | 30MG/100ML (0.3MG/ML) | SOLUTION;INTRAVENOUS | Prescription | Yes | AP | 209176 | MITSUBISHI TANABE |
SOLUTION;INTRAVENOUS; 60MG/100ML (0.6MG/ML)
TE Code = AP
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | TE Code | Application No. | Company |
---|---|---|---|---|---|---|---|---|
EDARAVONE | EDARAVONE | 60MG/100ML (0.6MG/ML) | SOLUTION;INTRAVENOUS | Prescription | No | AP | 215917 | DR REDDYS |
EDARAVONE | EDARAVONE | 60MG/100ML (0.6MG/ML) | SOLUTION;INTRAVENOUS | Prescription | No | AP | 216199 | GLAND PHARMA LTD |
RADICAVA | EDARAVONE | 60MG/100ML (0.6MG/ML) | SOLUTION;INTRAVENOUS | Prescription | Yes | AP | 209176 | MITSUBISHI TANABE |